Astrana Health SEC Filings

Astrana Health, Inc. furnished an updated corporate investor presentation for May 2026. The company plans to use these slides at conferences and meetings, and has attached them as Exhibit 99.1. The material is expressly treated as furnished, not filed, which limits potential securities law liabilities.

The accompanying presentation outlines Astrana’s business mix across Medicare, Medicaid, commercial and other third-party payers, and highlights revenue categories such as capitation, risk pool settlements, management fees and fee-for-service. It also includes a chart of general and administrative expenses and G&A as a percentage of revenue over 2023–2026E.

Astrana Health, Inc. reported strong growth for the quarter ended March 31, 2026, driven by its value-based care model and the 2025 Prospect acquisition. Total revenue rose to $965.1 million, up from $620.4 million a year earlier, with capitation revenue reaching $892.9 million.

Net income attributable to Astrana increased to $14.4 million from $6.7 million, and diluted earnings per share improved to $0.29 from $0.14. Operating income was $28.5 million as higher medical and administrative costs followed the larger network.

Astrana ended the quarter with $478.4 million in cash and cash equivalents and total assets of $2.36 billion, including $874.8 million of goodwill from acquisitions. Long-term debt stood at $1.04 billion, largely from financing the Prospect deal, and medical liabilities were $439.3 million, reflecting obligations under its risk-bearing contracts.

Astrana Health, Inc. reported strong first quarter 2026 results, with total revenue of $965,100 (thousands), up 56% from the prior-year quarter. Net income attributable to Astrana was $14,436 (thousands), and diluted EPS doubled to $0.29.

Non-GAAP performance also improved, as Adjusted EBITDA rose to $66,298 (thousands), a year-over-year increase of 82%, and Adjusted EPS – diluted reached $0.74. Free cash flow increased to $64,056 (thousands), up 372% year over year, while cash and cash equivalents grew to $478,383 (thousands).

The company reaffirmed 2026 guidance, targeting total revenue between $3,800,000 and $4,100,000 (thousands), Adjusted EBITDA between $250,000 and $280,000 (thousands), and free cash flow between $105,000 and $132,500 (thousands). Management highlighted growth in full-risk value-based arrangements and continued deployment of its AI-enabled care platform.

Astrana Health, Inc. is holding its 2026 Annual Meeting on June 10, 2026 to vote on four key items: electing nine directors, ratifying Ernst & Young LLP as auditor, approving an advisory say-on-pay vote, and expanding its 2024 Equity Incentive Plan.

The equity plan amendment would increase the shares of common stock reserved for issuance from 4,100,000 to 5,100,000 and extend the plan’s term. As of the April 14, 2026 record date, Astrana had 55,713,532 common shares outstanding, and its largest stockholder, APC, held 6,132,802 shares, subject to a 9.99% voting cap.

Astrana Health, Inc. COO and CFO Basho Chandan surrendered 3,870 shares of common stock at $29.07 per share on April 14, 2026 to cover tax withholding obligations on newly vested restricted stock. After this tax-withholding disposition, he directly holds 167,765 shares, including 30,404 unvested restricted shares and additional restricted stock units scheduled to vest through 2027.

Lam Thomas S. reported acquisition or exercise transactions in this Form 4 filing.

Astrana Health, Inc. director Thomas S. Lam received an equity award of 41,667 restricted stock units (RSUs) of common stock on April 6, 2026. The RSUs carry no purchase price and represent a compensation grant, not an open-market share purchase.

Each RSU is a contingent right to one Astrana common share. The award will vest in eight equal semi-annual installments beginning on October 6, 2026, provided Lam remains employed with Astrana Health and/or its affiliates. After this grant, he directly holds 465,657 shares of common stock, including other previously granted restricted stock and RSUs subject to multi-year vesting schedules.

Separate from his direct holdings, Lam is reported as having indirect interests in 6,132,802 shares held by Allied Physicians of California, a Professional Medical Corporation, where he serves as CEO, CFO, director and stockholder, and 1,133,706 shares held by the Thomas and Jeanette Lam 2002 Family Trust. He disclaims beneficial ownership of the Allied Physicians shares except to the extent of his pecuniary interest.

Sim Kenneth T. reported acquisition or exercise transactions in this Form 4 filing.

Astrana Health, Inc. Executive Chairman Kenneth T. Sim received a grant of 100,000 restricted stock units of common stock as compensation. Each unit represents one share and vests in eight equal semi-annual installments beginning on October 6, 2026, if he remains employed. After this award, he directly holds 739,407 common shares, including other unvested restricted stock and restricted stock units with vesting schedules extending into 2027. He also has additional indirect holdings through various trusts and entities where he disclaims full beneficial ownership.

Sim Brandon reported acquisition or exercise transactions in this Form 4 filing.

Astrana Health, Inc. CEO and President Brandon Sim reported an equity compensation grant in the form of 201,056 restricted stock units, each representing a right to receive one share of common stock. These units are scheduled to vest in eight equal semi-annual installments beginning on October 6, 2026, subject to continued employment. Following this grant, Sim directly holds 1,246,385 shares of common stock, including other unvested restricted stock and restricted stock units. The filing also notes indirect holdings in the Sim Family Irrevocable Trust 2021 and the Brandon Sim 2020 Irrevocable Trust, for which Sim disclaims beneficial ownership except for any pecuniary interest.